Micro 204 Tumor Immunology.

Size: px
Start display at page:

Download "Micro 204 Tumor Immunology."

Transcription

1 Micro 204 Tumor Immunology

2 Part 1 Immunosurveillance & Immunoediting Tumor Antigens - definition & discovery Part 2 Cancer Immunotherapy

3 Immunological Surveillance Ehrlich, Burnet & Thomas Paul Ehrlich (1909) Concept of cancer immunosurveillance. Predicted that cancer would occur at incredible frequency if host defenses did not prevent the outgrowth of continuously arising cancer cells Lewis Thomas (1957) primary function of cellular immunity.is to protect from neoplastic disease Macfarland Burnet (1957) It is by no means inconceivable that small accumulations of tumour cells may develop and because of their possession of new antigenic potentialities provide an effective immunological reaction with regression of this tumor and no clinical hint of its existence

4 Evidence for immune surveillance in humans Increased incidence of EBV+ B cell lymphomas in transplant patients treated with immunosuppressive drugs Increased incidence of Kaposi s sarcoma & EBV+ B cell lymphomas in AIDS patients Gastric cancer associated with H. pylori infection Cervical cancer caused by human papillomavirus Liver cancer caused by hepatitis B & C

5 Anti-Tumor Effector Mechanisms CD4 + T cells, CD8 + CTL, and NK cells - direct cytotoxicity or ADCC (NK cells) via perforin & granzymes and/or TNF family members - cytokine release (e.g., TNF, IFNγ, GM-CSF) leading to: B cells a) lysis of tumor cells b) disruption of angiogenesis c) recruitment and activation of DC, macrophages, & granulocytes - production of tumor-specific antibodies leading to: a) complement-mediated killing b) ADCC c) antibody-mediated apoptosis by disrupting oncogenic signals Macrophages - killing via ADDC - killing via production of cytokines such as TNF - killing via production of toxic oxygen or nitrogen intermediates

6 Immunotherapy Strategies Cytokine infusions (e.g. IFNa, IL-2) Induction of inflammation (e.g. CpG) Innate System Tumor-targeted antibodies (e.g.,herceptin) Adoptive transfer of tumor-specific T cells Donor lymphocyte infusions after BMT/HSCT (allogeneic bone marrow or hematopoietic stem cell transplant) Vaccination Active Adaptive System Passive Adaptive System

7 Immune Surveillance - Revival Nature 410:1107, 2001

8

9 Spontaneous tumors in wild-type and immunodeficient mice

10 T cells control latent tumors Koebel et al. Nature;450:903, 2007

11 Tumors arising in immunodeficient mice are more immunogeneic that tumors arising in wild-type mice Assayed by transplanting tumors into wildtype or immunodeficient mice

12 Tumor Elimination - Equilibrium - Escape Schreiber et al. Immunity 2004

13 Zhang et al. NEJM 348:203, 2003 Tumor-infiltrating lymphocytes correlation with survival in ovarian cancer patients

14

15 Melan-A/MART-1-specific CD8 + T cells in lymph nodes of melanoma patients Romero et al. J. Exp. Med., Volume 188(9),

16 Tumor Antigens Tumor-specific antigens Expressed by tumors ONLY Tumor-associated antigens Preferentially expressed by tumors Oncofetal antigen Expressed by tumors in adult, but also expressed by fetal (not adult) tissues

17 Types of Tumor Antigens Recognized by T cells

18 Neo-epitopes

19

20 Cancer Research 68:889, 2008

21 Use of Human Tumor Ag-Specific Cloned CTL for Identification of Tumor Antigens

22 TNFa Production

23 Serological identification of tumor antigens - Serex Some cancer patients have antibodies reactive with their own tumor Use patients sera to expression clone the tumor antigens Surprizingly, many of the antisera recognized the same tumor-associated antigens that detected by CTL

24 Passive Immunotherapy Anti-tumor monoclonal antibodies (a billion dollar business)

25 Antibody-dependent cellular cytotoxicity

26 Rituxan Pivotal Trial: Treatment of Patients With Relapsed B Lymphoma Rituxan 375 mg/m 2 (IV) Weeks Monitoring every 3 months x2 years E valuable P atients 166 Overall Res pon s e 80 (48% ) Comp lete R es pon s e 10 (6% ) P artial Re s po ns e 70 (42% ) McLaughlin et al. J Clin Oncol. (1998) 16:2825

27 CD16 (FcγRIII) mediates Herceptin and Rituxan mediate human tumor elimination in nude mice

28

29 Active Immunotherapy Vaccination

30 First vaccine to prevent human cancer! vaccine for papilloma virus for cervical cancer!

31 Successful Active Vaccination against Virus-induced Cancers Vaccine to feline leukemia virus for cats Vaccine to herpes virus (Marek s virus) in chickens Vaccine to hepatitis B in humans to prevent liver carcinoma Vaccination to HPV prevents cervical cancer

32 Active Immunization - Tumor cells or antigens Tumor cells or extracts (Melacin) Tumor peptide + adjuvant vaccine Tumor peptide loaded on dendritic cell Tumor antigen cdna vaccination Tumor antigen in recombinant virus Feeding dendritic cells dead tumors Feeding dendritic cells tumor RNA

33 Provenge load autologous DC with prostatic acid phosphatase inject into prostate cancer patient

34 Mechanisms of Tumor Escape from Immune Responses Loss of MHC or TAP Loss of co-stimulatory molecules Antigenic variation Secretion of immunosuppressive factors E.g. TGF-β, IL-10 T cells don t penetrate solid tumors Exhaustion of T cells T regulatory cells suppress anti-tumor responses

35 Cancer immunotherapy in the clinic Lawrence Fong Professor of Medicine

36 Immune recogni1on of cancer (Chen and Mellman, Immunity 2013)

37 Candidate targets for immunotherapy TNF-α IFN-α IFN-γ TGF-β (Chen and Mellman, Immunity 2013)

38 Co-s1mula1on and co-inhibi1on Antigen-presenting cell PDL1 or PDL2 T cell? + PDL1 or PDL2 PD1 CD80 or CD86 CD28 + CD80 or CD86 CTLA4 B7RP1 ICOS + B7-H3? B7-H4? HVEM MHC class I or II CD137L Peptide BTLA KIR TCR LAG3 CD137 Signal 1 + OX40L OX40 + CD70 CD CD40 CD40L GAL9 Adenosine TIM3 A2aR (Pardoll. NRC 2012) Cytokines (TGFβ, IL-1, IL-6, IL-10, IL-12, IL-18)

39 An--CTLA-4 in metasta-c Patients with metastatic melanoma Ipilimumab vs. vaccine/ipilimumab vs. vaccine OS: 10 vs vs. 6.4 months FDA approved 3/2011 melanoma (Hodi et al, NEJM 2010)

40 B Target-Lesion Change in Dacarbazine Group 100 zine group who had a response, 14 did not hav rable response. The dashed line in Panel C indi the median duration of response. An--PD-1 in metasta-c 0 A Overall Survival Patients Surviving (%) No. at Risk Nivolumab Dacarbazine Nivolumab Dacarbazine 50/210 96/208 melanoma 75 Hazard ratio for death, 0.42 (99.79% CI, ) P<0.001 Patients Who Died Median Survival no./total no. mo (95% CI) Not reached 10.8 ( ) Dacarbazine A Target-Lesion Change in Nivolumab Group 100 Maximum Change from Baseline (%) Months Nivolumab Maximum Change from Baseline (%) B Target-Lesion Change in Dacarbazine Group Maximum Change from Baseline (%) C Duration of Response 100 Patients with Complete or Partial Response (%) No. at Risk Nivolumab Dacarbazine n engl j med 372;4 nejm.org january 22, The New England Journal of Medicine Downloaded 50 from nejm.org at SAN FRANCISCO (UCSF) on January 20, For personal use only. No other uses without pe Copyright 2015 Massachusetts Medical Society. All rights reserved Nivolumab Dacarbazine Patients Dacarbazine Patients without a Durable Response no./total no. 12/84 14/ Months 23 1 Nivolumab Median Duration of Response mo (95% CI) Not reached 6.0 (3.0 not reached) or 4 selected adverse events that were con to be related to nivolumab treatment we quent and included diarrhea and an eleva nine aminotransferase level (each in 1 patients) (Table S4 in the Supplementary dix). The majority of selected adverse e grade 3 or 4 resolved quickly with a dela study treatment, glucocorticoid adminis or both, as recommended in the safety m ment guidelines for nivolumab (Table S Supplementary Appendix). DISCUSSION This phase 3, double-blind, randomize trolled study showed an overall survival with nivolumab, an anti PD-1 antibody. of death decreased by 58% with nivolu compared with dacarbazine, among pr untreated patients with advanced me The survival benefit was consistent acros prespecified subgroups, including patien poor prognostic factors. The 1-year survival rate associate nivolumab in this study (73%) is consiste the results in a phase 1 study 15,16,22 a significantly higher than the rate as with dacarbazine. Dacarbazine was ch the comparator because, until recently, standard first-line treatment in many c for patients who had melanoma without 100 (Robert et al. NEJM 2015) Patients 100 Patients

41 Combining an--ctla-4 and an-- PD Nivolumab plus Ipilimumab Median Change: Decrease of 68.1% Ipilimumab Median Change: Increase of 5.5% Best Change from Baseline in Target-Lesion Volume (%) * * * ** * * * * ** **** ** * * ********* *** ** * * 100 * ************ * Patient with confirmed response Patients (Postow et al. NEJM 2015) Table 2. Response to Treatment. Variable Best overall response no. (%)* Nivolumab plus Ipilimumab (N = 72) Patients with BRAF Wild-Type Tumors Ipilimumab (N = 37) Patients with BRAF V600 Mutation Positive Tumors Nivolumab plus Ipilimumab (N = 23) Complete response 16 (22) 0 5 (22) 0 Ipilimumab (N = 10) Partial response 28 (39) 4 (11) 7 (30) 1 (10) Stable disease 9 (12) 13 (35) 3 (13) 1 (10) Progressive disease 10 (14) 15 (41) 5 (22) 7 (70) Could not be determined 9 (12) 5 (14) 3 (13) 1 (10) Patients with objective response no. (% [95% CI]) 44 (61 [49 72]) 4 (11 [3 25]) 12 (52 [31 73]) 1 (10 [0 45])

42 Combining an--ctla-4 and an-- PD-1 B C During treatment First response After treatment discontinuation Ongoing response Nivolumab plus Ipilimumab Ipilimumab 100 Death or Disease Progression no. of patients/total no. Median Progression-free Survival mo (95% CI) 30/72 NR 25/ ( ) Hazard ratio, 0.40 (95% CI, ) P< Patients Nivolumab plus Ipilimumab Progression-free Survival (% of patients) Nivolumab plus ipilimumab (N=72) Ipilimumab (N=37) Durability of Response (wk) Ipilimumab No. at Risk Nivolumab plus ipilimumab Ipilimumab Months (Postow et al. NEJM 2015)

43 Adop-ve CELL THERAPY (ACT) Tumor is resected and cut into small fragments Tumor fragments are grown in mul1ple cultures containing highdose IL-2 Tumor infiltra1ng lymphocytes (TILs) are expanded for ~3 weeks Expanded TILs are assayed and pooled for reinfusion awer condi1oning lymphodeple1ng chemotherapy Rosenberg SA, et al. Nature Reviews Cancer 2008;8:

44 Chimeric an-gen receptor (CAR) T cells Specificity of a monoclonal an1body Not dependent on MHC Ac1vates T cells with Signals 1 & 2 Sample CAR gene construct (CD28) ê Effector func-on

45 Published OnlineFirst April 2, 2013; DOI: / CD- Genera1ons of CARs Making Better Chimeric Antigen Receptors First-generation CAR activation only Second-generation CAR dual signaling Third-generation CAR multiple ( 3) signaling mab scfv Spacer 0X BB 0X-40 CD28 ICOS ζ or FcRγ CD28 4-1BB TM Figure 1. generation C as CD8/CD3 middle, seco ing to direct signals; righ complex str mab, monoc T-body Lck lacking. Finally, the effec engineering and the modular nature of their structure, CARs defined. CARs typically ta are rapidly evolving and show great promise for their successlittle is known about mi ful use in a wide range of immunotherapies. CARs are as exqu (Sadelain etwhether al. Can Disc 2013) lesser sensitivity could rep CAR TARGETING against tumors expressin

46 The new england journal of medicine Original Article Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia Shannon L. Maude, M.D., Ph.D., Noelle Frey, M.D., Pamela A. Shaw, Ph.D., Richard Aplenc, M.D., Ph.D., David M. Barrett, M.D., Ph.D., Nancy J. Bunin, M.D., Anne Chew, Ph.D., Vanessa E. Gonzalez, M.B.A., Zhaohui Zheng, M.S., Simon F. Lacey, Ph.D., Yolanda D. Mahnke, Ph.D., Jan J. Melenhorst, Ph.D., Susan R. Rheingold, M.D., Angela Shen, M.D., David T. Teachey, M.D., Bruce L. Levine, Ph.D., Carl H. June, M.D., David L. Porter, M.D., and Stephan A. Grupp, M.D., Ph.D x 10^6 to 20.6 x 10^6 CTL019 clles/kg IV 27/30 (90%) children and adults with relapsed ALL achieved complete remission. All pa1ents developed a cytokine release syndrome. 73% with relapse-free B cell aplasia. (Maude, NEJM 10/2014)

47 A Probability of Event-free Survival No. of Patients Survival rate at 6 mo, 67% (95% CI, 51 88) Months since Infusion A Detection of CTL019+ Cells in Peripheral Blood Patient No Months C Levels of CTL019 DNA in Peripheral Blood 100,000 Positive Negative First confirmed negative Relapse B Time to First Negative Test Probability of Persistence Months since Infusion No. of Patients B Probability of Overall Survival Survival rate at 6 mo, 78% (95% CI, 65 95) Copies/µg of Genomic DNA 10,000 1, No. of Patients Months since Infusion Months since Infusion (Maude, NEJM 10/2014)

48 Cytokine Release Syndrome Fever Hypotension requiring vasopressors Hypoxemia requiring mechanical ven1la1on A Level of Interleukin-6 Interleukin-6 (pg/ml) 100,000 10,000 1, P< No Yes Severe Cytokine-Release Syndrome B Baseline Disease Burden Percent of Blast Cells in Bone Marrow P= No Yes Severe Cytokine-Release Syndrome B Baseline Disease Burden (Maude, NEJM 10/2014)

49 Discussion Groups 1. What is the best cell or cells for CAR therapy? CD8 + T cells, CD4 + T cells, γδ T cells, NK cells? Macrophages? 2. How would you make an off-the-shelf CAR T cell population that could be introduced into allogeneic recipients? 3. In addition to introducing a CAR into T cells, how else might you genetically modify the recipient cells to make them more effective or more safe?

Priming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics

Priming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer

More information

Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)

Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer) Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of

More information

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent

More information

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand

More information

Immune surveillance hypothesis (Macfarlane Burnet, 1950s)

Immune surveillance hypothesis (Macfarlane Burnet, 1950s) TUMOR-IMMUNITÄT A.K. Abbas, A.H. Lichtman, S. Pillai (6th edition, 2007) Cellular and Molecular Immunology Saunders Elsevier Chapter 17, immunity to tumors Immune surveillance hypothesis (Macfarlane Burnet,

More information

Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant

Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be

More information

Darwinian selection and Newtonian physics wrapped up in systems biology

Darwinian selection and Newtonian physics wrapped up in systems biology Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid

More information

Exploring Immunotherapies: Beyond Checkpoint Inhibitors

Exploring Immunotherapies: Beyond Checkpoint Inhibitors Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction

More information

Imm 532 2/25/16. Tumor Immunology. Phil Greenberg

Imm 532 2/25/16. Tumor Immunology. Phil Greenberg Imm 532 2/25/16 Tumor Immunology Phil Greenberg Tumor Immunology Study of the interactions between the immune system and cancer - antigenic properties of tumor cells - host immune response to tumor cells

More information

Cancer immunity and immunotherapy. General principles

Cancer immunity and immunotherapy. General principles 1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or

More information

CANCER IMMUNOPATHOLOGY. Eryati Darwin Faculty of Medicine Andalas University

CANCER IMMUNOPATHOLOGY. Eryati Darwin Faculty of Medicine Andalas University CANCER IMMUNOPATHOLOGY Eryati Darwin Faculty of Medicine Andalas University Padang 18 Mei 2013 INTRODUCTION Tumor: cells that continue to replicate, fail to differentiate into specialized cells, and become

More information

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor

More information

Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD

Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.

More information

Abstract #163 Michael Kalos, PhD

Abstract #163 Michael Kalos, PhD LONG TERM FUNCTIONAL PERSISTENCE, B CELL APLASIA AND ANTI LEUKEMIA EFFICACY IN REFRACTORY B CELL MALIGNANCIES FOLLOWING T CELL IMMUNOTHERAPY USING CAR REDIRECTED REDIRECTED T CELLS TARGETING CD19 Abstract

More information

Personalized medicine - cancer immunotherapy

Personalized medicine - cancer immunotherapy Personalized medicine - cancer immunotherapy Özcan Met, PhD Senior Staff Scientist, Cell Therapy Director Center for Cancer Immune Therapy Department of Hematology Department of Oncology University Hospital

More information

Tumor Immunology. Tumor (latin) = swelling

Tumor Immunology. Tumor (latin) = swelling Tumor Immunology Tumor (latin) = swelling benign tumor malignant tumor Tumor immunology : the study of the types of antigens that are expressed by tumors how the immune system recognizes and responds to

More information

2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery

2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical

More information

5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)

5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Immune surveillance 5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Transplanted patients following an immunosuppressor therapy are 80 times more likely to develop

More information

Immunotherapy, an exciting era!!

Immunotherapy, an exciting era!! Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy

More information

Immunotherapy of HNC: immune mechanisms and therapeutic targets

Immunotherapy of HNC: immune mechanisms and therapeutic targets Immunotherapy of HNC: immune mechanisms and therapeutic targets Ourania Tsitsilonis, MD, PhD Department of Biology National & Kapodistrian University of Athens What does the Immune System see in Cancer?

More information

Immunotherapy: The Newest Treatment Route

Immunotherapy: The Newest Treatment Route Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William

More information

THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER

THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum

More information

The next steps for effective cancer immunotherapy and viral vaccines. Peter Selby FACP(UK)

The next steps for effective cancer immunotherapy and viral vaccines. Peter Selby FACP(UK) The next steps for effective cancer immunotherapy and viral vaccines Peter Selby FACP(UK) Richard Alan Steve Sasha Matt Nav Vile Melcher Griffin Zougman Bentham Vasudev Adel Nick Gemma Liz Samson Hornigold

More information

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3

More information

Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017

Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY

More information

Emerging Targets in Immunotherapy

Emerging Targets in Immunotherapy Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy

More information

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Identifying Appropriate Patients and Maximizing Outcomes. Shannon L.

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Identifying Appropriate Patients and Maximizing Outcomes. Shannon L. CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Identifying Appropriate Patients and Maximizing Outcomes Shannon L. Maude, MD, PhD CTL019 cell Lentiviral vector Anti-CD19 CAR construct CD19 Native

More information

Bihong Zhao, M.D, Ph.D Department of Pathology

Bihong Zhao, M.D, Ph.D Department of Pathology Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories

More information

Immunotherapy Overview, Rationale, and Role in Clinical Practice

Immunotherapy Overview, Rationale, and Role in Clinical Practice Immunotherapy Overview, Rationale, and Role in Clinical Practice Financial Disclosure Bradi L. Frei, PharmD, BCOP, BCPS has no relevant financial relationships with commercial interests to disclose. OBJECTIVES

More information

IMMU 7630 Fall 2018 TUMOR IMMUNOLOGY

IMMU 7630 Fall 2018 TUMOR IMMUNOLOGY TUMOR IMMUNOLOGY CANCER. About 610,000 people in the United States will die of cancer in 2018 1. It is the second leading cause of death, after heart disease. After accidents, it is the second leading

More information

3. A small percentage of tumors, mainly melanomas and some lymphomas, spontaneously regress, presumably due to an immunologic response.

3. A small percentage of tumors, mainly melanomas and some lymphomas, spontaneously regress, presumably due to an immunologic response. TUMOR IMMUNOLOGY CANCER. Over 565,000 people in the United States died of cancer in 2008 1. It is the second leading cause of death, after heart disease. After accidents, it is the second leading cause

More information

Professor Mark Bower Chelsea and Westminster Hospital, London

Professor Mark Bower Chelsea and Westminster Hospital, London Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing

More information

Tumor Immunology: A Primer

Tumor Immunology: A Primer Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

International Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting

International Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting International Society of Breast Pathology USCAP 2017 Annual Meeting Immune Targeting in Breast Cancer Ashley Cimino-Mathews, MD Assistant Professor of Pathology and Oncology The Johns Hopkins Hospital

More information

3. A small percentage of tumors, mainly melanomas and some lymphomas, spontaneously regress, presumably due to an immunologic response.

3. A small percentage of tumors, mainly melanomas and some lymphomas, spontaneously regress, presumably due to an immunologic response. TUMOR IMMUNOLOGY CANCER. Over 577,000 people in the United States will die of cancer in 2012 1. It is the second leading cause of death, after heart disease. After accidents, it is the second leading cause

More information

Immunology CANCER IMMUNOLOGY

Immunology CANCER IMMUNOLOGY Immunology د. عائدة الدرزي Lec. 6 CANCER IMMUNOLOGY Oncogenesis (passes through two stages): 1- Reversible change Normal transformed cells 2- Irreversible change Transformed oncogenic cells Factors causing

More information

Engineered Immune Cells for Cancer Therapy : Current Status and Prospects

Engineered Immune Cells for Cancer Therapy : Current Status and Prospects When Engineering Meets Immunology Engineered Immune Cells for Cancer Therapy : Current Status and Prospects Yong Taik Lim, Ph.D. Nanomedical Systems Laboratory (http://www.nanomedicalsystems.org) SKKU

More information

Immunotherapy of Prostate Cancer

Immunotherapy of Prostate Cancer Immunotherapy of Prostate Cancer Robert E. Reiter MD MBA Bing Professor of Urologic Oncology Geffen School of Medicine at UCLA Costimulatory expression required for T cell activation Therapeutic Vaccines

More information

Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use

Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org

More information

Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School

Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School CTLs, Natural Killers and NKTs 1 Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School CTL inducing tumor apoptosis 3 Lecture outline CD8 + Cytotoxic T lymphocytes (CTL) Activation/differentiation

More information

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?

More information

CANCER IMMUNOTHERAPY. Cancer Research Center, Dpt. of Medicine & Service of Cytometry University of Salamanca. IBSAL

CANCER IMMUNOTHERAPY. Cancer Research Center, Dpt. of Medicine & Service of Cytometry University of Salamanca. IBSAL FARMAFORUM 2015 FACULTAD FARMACIA CANCER IMMUNOTHERAPY Cancer Research Center, Dpt. of Medicine & Service of Cytometry University of Salamanca. IBSAL The immune response to tumors Oncogenic event The immune

More information

08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells

08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines

More information

Focus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct

Focus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley

More information

RXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals

RXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private

More information

Immuno-Oncology Applications

Immuno-Oncology Applications Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures

More information

Brave New World of Cancer Therapeutics (Back to the Future)

Brave New World of Cancer Therapeutics (Back to the Future) Brave New World of Cancer Therapeutics (Back to the Future) Alexandra M. Levine, MD, MACP Chief Medical Officer Melinda & Norman Payson Professor of Medicine Professor of Hematology/HCT City of Hope National

More information

Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico.

Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico. Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico. Andrea Anichini Human Tumors Immunobiology Unit Dept. of Experimental Oncology and Molecular Medicine Immune checkpoint

More information

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President

More information

IMMUNOTARGET THERAPY: ASPETTI GENERALI

IMMUNOTARGET THERAPY: ASPETTI GENERALI IMMUNOTARGET THERAPY: ASPETTI GENERALI Alessandro Minisini Dipartimento di Oncologia Azienda Ospedaliero Universitaria Udine Verona, 19 settembre 2015 HALLMARKS OF CANCER Douglas Hanahan, Robert A. Weinberg,

More information

Basic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA

Basic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer

More information

BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION

BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION Zihai Li, M.D., Ph.D. Leader, Cancer Immunology Program Hollings Cancer Center Medical University of South Carolina (MUSC) DISCLOSURE GOALS Understand that immune

More information

Tumor Microenvironment and Immune Suppression

Tumor Microenvironment and Immune Suppression Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation

More information

IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER

IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix

More information

PTAC meeting held on 5 & 6 May (minutes for web publishing)

PTAC meeting held on 5 & 6 May (minutes for web publishing) PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and

More information

Cancer and the Immune System

Cancer and the Immune System NIFA Neue Impulse in Fortbildung und Ausbildung, AstraZeneca Onkologie Symposium, Vienna, October 20 th 2017 Cancer and the Immune System Translational Tumor Immunology Group, Ludwig Cancer Research Center

More information

Immunology Lecture 4. Clinical Relevance of the Immune System

Immunology Lecture 4. Clinical Relevance of the Immune System Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor

More information

Spontaneous. Tumour induction. Immunosuppression

Spontaneous. Tumour induction. Immunosuppression Tumor immunology is the study of : 1- The antigenic properties of the tumor cells 2- The host IR to these tumor cell 3- The immunologic consequences to the host of the growth of the malignant cells 4-

More information

Tumor immunology. Tried to make things a simple as they can get,,, hope that u enjoy it! ال تخافوا بس أربع صفحات وشوي

Tumor immunology. Tried to make things a simple as they can get,,, hope that u enjoy it! ال تخافوا بس أربع صفحات وشوي Tumor immunology Tried to make things a simple as they can get,,, hope that u enjoy it! ال تخافوا بس أربع صفحات وشوي Tumors can occur, they can be considered as something foreign that should be dealt with

More information

Immunity and Cancer. Doriana Fruci. Lab di Immuno-Oncologia

Immunity and Cancer. Doriana Fruci. Lab di Immuno-Oncologia Immunity and Cancer Doriana Fruci Lab di Immuno-Oncologia Immune System is a network of cells, tissues and organs that work together to defend the body against attacks of foreign invaders (pathogens, cancer

More information

Innovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD

Innovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD Innovations in Immunotherapy - Melanoma Systemic Therapies October 27, 2018 Charles L. Bane, MD Melanoma Prognosis Survival at 10 years Stage I: 90% Stage II: 60% Stage III: 40% Stage IV: 10% 2 Indications

More information

Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.

Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D. Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research

More information

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses

More information

Immunology and Immunotherapy 101 for the Non-Immunologist

Immunology and Immunotherapy 101 for the Non-Immunologist Immunology and Immunotherapy 101 for the Non-Immunologist Stephen P. Schoenberger, Ph.D La Jolla Institute for Allergy and Immunology & UCSD Moores Cancer Center Disclosures Human Longevity Inc: Salary

More information

Vaccins anti-cancer. Claude Leclerc. 7 novembre 2011

Vaccins anti-cancer. Claude Leclerc. 7 novembre 2011 Vaccins anti-cancer Claude Leclerc 7 novembre 2011 2010: FDA panel passes first cancer vaccine Cancer, a worldwide burden 1st cause of mortality in France In Europ, in 2006: - 1.7 million deaths from cancer

More information

Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?

Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE

More information

New Developments in Cancer Treatment. Dulcinea Quintana, MD

New Developments in Cancer Treatment. Dulcinea Quintana, MD New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4

More information

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC

More information

Marshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011

Marshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011 Marshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011 Most common form of cancer in adults ages 25-29 3-5% of skin cancers but 65-75% of deaths Most common metastasis to small

More information

Interleukin-2 Single Agent and Combinations

Interleukin-2 Single Agent and Combinations Interleukin-2 Single Agent and Combinations Michael K Wong MD PhD Norris Cancer Center University of Southern California mike.wong@med.usc.edu Disclosures Advisory Board Attendance Merck Bristol Myers

More information

Adoptive Cell Therapy: Treating Cancer

Adoptive Cell Therapy: Treating Cancer Adoptive Cell Therapy: Treating Cancer with Genetically Engineered T Cells Steven A. Feldman, Ph.D. Surgery Branch National Cancer Institute NCT Conference Heidelberg, Germany September 24, 2013 Three

More information

Interaction between the immune system and tumor

Interaction between the immune system and tumor Tumor immunology Interaction between the immune system and tumor elimination (immune system attempts to kill cancer cells and inhibits tumor growth) balance (between elimination and growth of tumor cells)

More information

2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery

2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery F141: Advanced Melanoma: Mechanisms of Immune Therapies beyond Checkpoint blockade Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los

More information

CAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER. Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th Paris

CAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER. Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th Paris CAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th 2018 - Paris Cellectis, 05-APR-2018 2 FORWARD-LOOKING STATEMENTS THIS PRESENTATION

More information

Harnessing the Immune System to Prevent Cancer: Basic Immunologic Mechanisms

Harnessing the Immune System to Prevent Cancer: Basic Immunologic Mechanisms Harnessing the Immune System to Prevent Cancer: Basic Immunologic Mechanisms (the language of immunology) Barbara K. Dunn NCI/Division of Cancer Prevention October 23, 2017 Harnessing the Immune System

More information

Advances in Adoptive Cellular Therapy of Cancer. Melanoma Bridge Meeting December 5, 2014

Advances in Adoptive Cellular Therapy of Cancer. Melanoma Bridge Meeting December 5, 2014 Advances in Adoptive Cellular Therapy of Cancer Melanoma Bridge Meeting December 5, 2014 David Stroncek, MD Chief, Cell Processing Section, DTM, CC, NIH Bethesda, Maryland, USA Disclosures None Focus

More information

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers

More information

Innate Immunity, Inflammation and Cancer

Innate Immunity, Inflammation and Cancer Innate Immunity, Inflammation and Cancer Willem Overwijk, Ph.D. Melanoma Medical Oncology Center for Cancer Immunology Research MD Anderson Cancer Center, Houston, TX SITC/MDACC -6/14/2013 www.allthingsbeautiful.com

More information

Micro 204. Cytotoxic T Lymphocytes (CTL) Lewis Lanier

Micro 204. Cytotoxic T Lymphocytes (CTL) Lewis Lanier Micro 204 Cytotoxic T Lymphocytes (CTL) Lewis Lanier Lewis.Lanier@ucsf.edu Lymphocyte-mediated Cytotoxicity CD8 + αβ-tcr + T cells CD4 + αβ-tcr + T cells γδ-tcr + T cells Natural Killer cells CD8 + αβ-tcr

More information

Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies

Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Jason Muhitch, PhD MIR 509 October 1 st, 2014 Email: jason.muhitch@roswellpark.org 0 Holy Grail of Tumor Immunity Exquisite

More information

The Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils

The Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy

More information

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015 Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib

More information

The immune response against cancer

The immune response against cancer The immune response against cancer Maries van den Broek Institute of Experimental Immunology vandenbroek@immunology.uzh.ch The immune system Main cells of the immune system Dendritic cell Monocyte Macrophage

More information

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes

More information

Immunotherapy for the Treatment of Cancer

Immunotherapy for the Treatment of Cancer Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,

More information

VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School

VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses Li Wang Dartmouth Medical School The B7 Immunoglobulin Super-Family immune regulators APC T cell Co-stimulatory:

More information

Disclosure Information. Mary L. Disis

Disclosure Information. Mary L. Disis Disclosure Information Mary L. Disis I have the following financial relationships to disclose: Consultant for: VentiRx, Celgene, Emergent, EMD Serono Speaker s Bureau for: N/A Grant/Research support from:

More information

Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL

Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections

More information

Immuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016

Immuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016 Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival

More information

9/22/2016. Introduction / Goals. What is Cancer? Pharmacologic Strategies to Treat Cancer. Immune System Modulation

9/22/2016. Introduction / Goals. What is Cancer? Pharmacologic Strategies to Treat Cancer. Immune System Modulation Immunomodulatory Therapies in Cancer Treatment Bill O Hara, PharmD, BCPS, BCOP Advanced Practice Pharmacist, Oncology/BMT Thomas Jefferson University Hospital Introduction / Goals What is Cancer? How can

More information

Lecture 17: Vaccines (Therapeutic and Prophylactic Types)

Lecture 17: Vaccines (Therapeutic and Prophylactic Types) Lecture 17: Vaccines (Therapeutic and Prophylactic Types) Therapeutic vaccines Bacillus Calmette Guerin (BCG; TheraCys) Very old agent initially developed as vaccine for MTB. Uses: Superficial bladder

More information

GENETICALLY ENHANCED CANCER THERAPIES

GENETICALLY ENHANCED CANCER THERAPIES GENETICALLY ENHANCED CANCER THERAPIES Hello! I am Tapani Ronni Science talks to translators and interpreters since 2012. You can find me at: www.polarbearcommunications.com ATA 2018 2 About the speaker

More information

Concepts of cancer immunotherapy

Concepts of cancer immunotherapy Concepts of cancer immunotherapy History Paul Ehrlich first conceived the idea that tumor cells can be recognized as foreign and eliminated by the immune system. Subsequently, Lewis Thomas and Macfarlane

More information

Immunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital

Immunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved

More information

Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology

Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy

More information

Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning

Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu HSL GeneticEpi Center,

More information

Where do these cells come from?

Where do these cells come from? Immunotherapy, and Personalized Medicine What Do They Mean? Community Lunch and Learn Presentation Thomas C. Shea, MD Professor of Medicine UNC Lineberger Comprehensive Cancer Center Where do these cells

More information

Cytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center

Cytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,

More information

TCR, MHC and coreceptors

TCR, MHC and coreceptors Cooperation In Immune Responses Antigen processing how peptides get into MHC Antigen processing involves the intracellular proteolytic generation of MHC binding proteins Protein antigens may be processed

More information

Bases for Immunotherapy in Multiple Myeloma

Bases for Immunotherapy in Multiple Myeloma Bases for Immunotherapy in Multiple Myeloma Paola Neri, MD, PhD Associate Professor of Medicine University of Calgary, Arnie Charbonneau Cancer Institute Disclosures Paola Neri MD, PhD Grants/research

More information